Trial population
diabetes, T2D, CHF
CHF, DIABETES
Patients between 18 and 85 years of age and who had a CHF with an ejection fraction below 40% (HFrEF) or an ejection fraction between 40 and 49% as well as a N-terminal pro-brain natriuretic peptide (NTproBNP) level > 125 pg/ml and at least one structural abnormality of the left atrium or ventricle (HFmrEF), in stable conditions, were included. Individuals were excluded, if they had any other form of diabetes than T2D, were treated with insulin or more than one oral anti-diabetic drug or any SGLT2 inhibitor within the last 10 weeks prior to the screening visit or were treated with loop diuretics (above furosemide > 80 mg/day, torasemide > 40 mg/day or piretanide > 6 mg/day), had an uncontrolled diabetes (glycated haemoglobin (HbA1c) ≥ 10% or fasting-plasma glucose level > 240 mg/dl) or uncontrolled blood pressure (BP ≥ 180/100 mmHg), had an estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m